Close Menu

NEW YORK – S2 Genomics said on Wednesday that it has signed distribution agreements with Scrum, PharmiGene, LnCBio, Thunderbio Science, and TrendBio to promote, sell, and support S2's Singulator 100 system as well as associated products for single-cell genomics and cell biology applications in the Asia-Pacific region.

The firm's agreements will cover Japan (Scrum), South Korea, (LnCBio and Thunderbio Science), Taiwan (PharmiGene), as well as Australia and New Zealand (TrendBio).

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.